|
(Correcting that Avacta Group is headquartered in London). Avacta Group PLC on Tuesday saw its shares climb higher as it reported two clinical updates to its faridoxorubicin, or AVA6000, clinical programme. AVA6000 is the London-based life sciences company’s lead pre|CISION programme. This platform is a proprietary payload delivery system designed to ‘concentrate highly potent payloads in the tumour microenvironment while sparing normal tissues.’ Avacta explained that agreed updates to the trial protocol include the removal of the maximum dosing limit and to allow flexibility in dosing levels. ‘These two developments underscore the growing confidence from investigators and regulators in the tolerability profile of faridoxorubicin and should support a smooth transition to future efficacy studies,’ the company said. Shares in the company were up 11% at 55.15 pence on Tuesday afternoon in London. Avacta said the historical dosing limit has been removed owing to the collection of ‘highly favourable’ safety data from the faridoxorubicin programme, and observation of patients getting the highest cumulative doses over prolonged periods. The company said its second ‘significant’ update is tied to the dose determination for the study in efficacy trials. Avacta said the final cohorts of patients with the selected indications in phase 1b will be enrolled allowing for two dose levels to be compared to determine the ‘optimal biologic dose’ in future trials. Chief Executive Christina Coughlin said: ‘These two critical steps in the development of our faridoxorubicin (AVA6000) program and by extension the proprietary pre|CISION platform demonstrate growing recognition by regulators of the safety of this platform.’ Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
